Compare · MDLN vs PLSE
MDLN vs PLSE
Side-by-side comparison of Medline Inc. (MDLN) and Pulse Biosciences Inc (PLSE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and PLSE operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.86B, about 13.4x PLSE ($3.49B).
- Over the past year, MDLN is down 12.5% and PLSE is up 188.9% - PLSE leads by 201.5 points.
- MDLN has been more active in the news (12 items in the past 4 weeks vs 7 for PLSE).
- MDLN has more recent analyst coverage (25 ratings vs 7 for PLSE).
- Company
- Medline Inc.
- Pulse Biosciences Inc
- Price
- -
- -
- Market cap
- $46.86B
- $3.49B
- 1M return
- -10.28%
- +49.09%
- 1Y return
- -12.54%
- +188.92%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2016
- News (4w)
- 12
- 7
- Recent ratings
- 25
- 7
Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.
Latest PLSE
- Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Needham initiated coverage on Pulse Biosciences with a new price target
- SEC Form 424B5 filed by Pulse Biosciences Inc
- Pulse Biosciences Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 10-Q filed by Pulse Biosciences Inc
- Pulse Biosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
- Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference
- Pulse Biosciences Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study